GUCA2B

GUCA2B encodes uroguanylin, an intestinal epithelial peptide hormone that binds and activates the receptor guanylyl cyclase C (GUCY2C) to regulate intestinal epithelial proliferation, metabolism, and barrier function (PMID:27688649). In the gut, GUCA2B is produced by spatially restricted epithelial populations: dispersed solitary tuft cell-like cells in human colon and duodenum (not the chromogranin A-positive enterochromaffin lineage) (PMID:27044258), secretory-lineage cells at the crypt base, and villus enterocytes in jejunum and ileum (PMID:27246004). Beyond local fluid/electrolyte signaling, uroguanylin acts as an endocrine satiety hormone: its postprandial secretion is suppressed by calorie-induced ER stress in diet-induced obese mice—an effect mimicked by tunicamycin and reversed by the chemical chaperone TUDCA (PMID:27214655)—and transgenic restoration of uroguanylin in the hypothalamus reconstitutes satiety and opposes visceral adiposity, glucose intolerance, and hepatic steatosis (PMID:27214655). Uroguanylin also exerts direct metabolic actions in peripheral tissues, stimulating lipolysis in human visceral adipocytes via hormone-sensitive lipase phosphorylation (PMID:27108812) and attenuating hepatocyte lipotoxicity and hepatic stellate cell fibrogenesis (PMID:37517791). In intestinal disease, GUCA2B together with GUCY2C is downregulated in inflamed IBD mucosa (PMID:25979109) and silenced by biallelic APC loss across the FAP adenoma-carcinoma sequence (PMID:32594830), with miR-27a-3p and miR-182-5p repressing GUCA2B to promote colorectal cancer cell proliferation (PMID:38767504).

1. 2016 Medium

   Establishing uroguanylin as an endogenous GUCY2C ligand defined the molecular axis through which GUCA2B controls intestinal epithelial homeostasis.

   Evidence Literature synthesis with functional pathway analysis of ligand-receptor activation

   PMID:27688649

   Open questions at the time

   • Summary rather than primary reconstitution data
   • Does not resolve receptor-binding affinity or downstream cGMP kinetics for uroguanylin specifically
2. 2016 Medium

   Mapping GUCA2B-expressing cells answered which intestinal cell types are the hormone's source, ruling out enterochromaffin cells in favor of dispersed tuft cell-like and secretory/enterocyte populations.

   Evidence In situ hybridization with lineage-marker co-expression in human, rat, and mouse intestine

   PMID:27044258 PMID:27246004

   Open questions at the time

   • Functional consequence of cell-type-restricted expression not tested
   • Regional differences between species not mechanistically explained
3. 2016 Medium

   Identifying calorie-induced ER stress as a suppressor of uroguanylin secretion explained how nutritional state controls hormone output and linked obesity to loss of the satiety signal.

   Evidence Diet-induced obese mouse model with tunicamycin/TUDCA pharmacological intervention and calorie-restriction rescue

   PMID:27214655

   Open questions at the time

   • Molecular mechanism coupling ER stress to GUCA2B transcription unresolved
   • Single lab, mouse only
4. 2016 Medium

   Brain-specific transgenic restoration established uroguanylin as a bona fide endocrine gut-brain satiety hormone rather than a purely local intestinal factor.

   Evidence Camk2a-Cre-ER(T2) hypothalamic Guca2b transgenic mouse with food intake and metabolic readouts

   PMID:27214655

   Open questions at the time

   • Central receptor and circuit mediating satiety not defined
   • Relevance to human obesity not tested
5. 2016 Medium

   Demonstrating direct lipolytic action on visceral adipocytes extended uroguanylin's role beyond the gut to peripheral lipid metabolism.

   Evidence In vitro incubation of human omental adipocytes with measurement of HSL phosphorylation and fatty acid/glycerol release

   PMID:27108812

   Open questions at the time

   • GUCY2C-dependence of the adipocyte effect not confirmed
   • In vitro only
6. 2015 Medium

   Showing coordinate downregulation of GUCA2B and GUCY2C in inflamed mucosa linked the hormone-receptor axis to intestinal inflammation and barrier dysfunction.

   Evidence Microarray, IHC, and ISH in human IBD biopsies and rat TNBS colitis with cytokine correlation

   PMID:25979109

   Open questions at the time

   • Causality versus consequence of inflammation not established
   • GUCA2B-specific cytokine correlation less characterized than GUCA2A
7. 2020 Medium

   Linking GUCA2B silencing to biallelic APC loss placed hormone loss at a defined genetic step in the colorectal adenoma-carcinoma sequence.

   Evidence Genetic mouse models with mono/biallelic Apc deletion corroborated by FAP patient tissue

   PMID:32594830

   Open questions at the time

   • Transcriptional mechanism connecting APC/Wnt to GUCA2B not defined
   • Whether hormone loss drives or accompanies tumorigenesis unresolved
8. 2023 Medium

   Direct effects on hepatocytes, stellate cells, and β-cells revealed uroguanylin as a broader metabolic protector against lipotoxicity and fibrosis.

   Evidence In vitro lipotoxic/profibrogenic treatment of HepG2, LX-2, and RIN-m5F cells with mitochondrial, fibrosis, and insulin readouts

   PMID:37274331 PMID:37517791

   Open questions at the time

   • Receptor mediating extra-intestinal effects not identified
   • In vivo validation absent
   • Divergence between guanylin and uroguanylin actions unexplained
9. 2024 Medium

   Identifying miR-27a-3p and miR-182-5p as repressors of GUCA2B added a post-transcriptional layer controlling the hormone axis in colorectal cancer growth.

   Evidence miRNA inhibitor transfection in HCT116 cells with mRNA/protein and proliferation assays

   PMID:38767504

   Open questions at the time

   • Direct miRNA-3'UTR binding not demonstrated
   • Single cell line, no in vivo confirmation
10. 2023 Low

    scRNA-seq inferred enterocyte-derived Guca2b signaling to GUCY2C on stem, TA, Paneth, and goblet cells during ischemia-reperfusion, framing the hormone as a mediator of crypt intercellular communication.

    Evidence Single-cell RNA-seq ligand-receptor inference in mouse ischemia-reperfusion model

    PMID:37577387

    Open questions at the time

    • Computational inference without experimental validation of the interaction
    • Functional role in injury repair untested

• Whether uroguanylin's peripheral metabolic actions (adipocyte, hepatic, β-cell) and its central satiety effect are all mediated through GUCY2C or via additional receptors remains unresolved.
• No receptor identified for extra-intestinal effects
• No structural model of uroguanylin-GUCY2C engagement in the corpus
• Human therapeutic translation untested